These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 9727872)
1. Combined solid-phase/solution synthesis of a 31-residue vasoactive intestinal peptide analog: general method for repetitive coupling of fragments without isolation and purification of intermediates. Felix AM; Zhao Z; Lambros T; Ahmad M; Liu W; Daniewski A; Michalewsky J; Heimer EP J Pept Res; 1998 Aug; 52(2):155-64. PubMed ID: 9727872 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of vasoactive intestinal peptide (VIP) via the mixed anhydride method. Schaaper WM; Beyerman HC Peptides; 1984; 5(2):167-8. PubMed ID: 6473149 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, conformational studies and biological activities of VIP and related fragments. Fournier A; Saunders JK; St-Pierre S Peptides; 1984; 5(2):169-77. PubMed ID: 6473150 [TBL] [Abstract][Full Text] [Related]
4. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366 [TBL] [Abstract][Full Text] [Related]
5. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Bolin DR; Michalewsky J; Wasserman MA; O'Donnell M Biopolymers; 1995; 37(2):57-66. PubMed ID: 7893947 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies of vasoactive intestinal peptide (VIP): cyclic disulfide analogs. Bolin DR; Cottrell J; Garippa R; O'Neill N; Simko B; O'Donnell M Int J Pept Protein Res; 1993 Feb; 41(2):124-32. PubMed ID: 8384606 [TBL] [Abstract][Full Text] [Related]
7. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Moreno D; Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P Peptides; 2000 Oct; 21(10):1543-9. PubMed ID: 11068102 [TBL] [Abstract][Full Text] [Related]
8. Redox-active bis-cysteinyl peptides. I. Synthesis of cyclic cystinyl peptides by conventional methods in solution and on solid supports. Musiol HJ; Siedler F; Quarzago D; Moroder L Biopolymers; 1994 Nov; 34(11):1553-62. PubMed ID: 7827266 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of a hydrophilic affinity matrix for the purification of the vasoactive intestinal peptide receptor. Fournier A; Couvineau A; Laburthe M Anal Biochem; 1993 Jun; 211(2):305-10. PubMed ID: 8391225 [TBL] [Abstract][Full Text] [Related]
10. Structure-activity studies on the vasoactive intestinal peptide pharmacophore. 1. Analogs of tyrosine. Bolin DR; Cottrell J; Garippa R; Michalewsky J; Rinaldi N; Simko B; O'Donnell M Int J Pept Protein Res; 1995; 46(3-4):279-89. PubMed ID: 8537181 [TBL] [Abstract][Full Text] [Related]
11. Solid-phase synthesis of chicken vasoactive intestinal peptide by a mild procedure using N alpha-9-fluorenylmethyloxycarbonyl amino acids. Colombo R Int J Pept Protein Res; 1982 Jan; 19(1):71-8. PubMed ID: 7118383 [TBL] [Abstract][Full Text] [Related]
12. Solid-phase synthesis of porcine vasoactive intestinal peptide. Coy DH; Gardner J Int J Pept Protein Res; 1980 Jan; 15(1):73-8. PubMed ID: 7358460 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of thymosin alpha 1 by fragment condensation using tert.-butyl side chain protection. Felix AM; Heimer EP; Wang CT; Lambros TJ; Swistok J; Roszkowski M; Ahmad M; Confalone D; Scott JW; Parker D Int J Pept Protein Res; 1985 Aug; 26(2):130-48. PubMed ID: 4066151 [TBL] [Abstract][Full Text] [Related]
14. The use of crown ethers in peptide chemistry-V. Solid-phase synthesis of peptides by the fragment condensation approach using crown ethers as non-covalent protecting groups. Botti P; Ball HL; Lucietto P; Pinori M; Rizzi E; Mascagni P J Pept Sci; 1996; 2(6):371-80. PubMed ID: 9230465 [TBL] [Abstract][Full Text] [Related]
15. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle. Chakder S; Rattan S J Pharmacol Exp Ther; 1993 Jul; 266(1):392-9. PubMed ID: 8392560 [TBL] [Abstract][Full Text] [Related]
16. Radiolabeling and in vitro and in vivo characterization of [18F]FB-[R(8,15,21), L17]-VIP as a PET imaging agent for tumor overexpressed VIP receptors. Cheng D; Yin D; Li G; Wang M; Li S; Zheng M; Cai H; Wang Y Chem Biol Drug Des; 2006 Dec; 68(6):319-25. PubMed ID: 17177894 [TBL] [Abstract][Full Text] [Related]
17. Antagonistic effect of a vasoactive intestinal peptide fragment, vasoactive intestinal peptide(1-11), on guinea pig trachea smooth muscle relaxation. Goossens JF; Pommery N; Lohez M; Pommery J; Helbecque N; Cotelle P; Lhermitte M; Henichart JP Mol Pharmacol; 1992 Jan; 41(1):104-9. PubMed ID: 1732717 [TBL] [Abstract][Full Text] [Related]
18. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. O'Donnell M; Garippa RJ; Rinaldi N; Selig WM; Simko B; Renzetti L; Tannu SA; Wasserman MA; Welton A; Bolin DR J Pharmacol Exp Ther; 1994 Sep; 270(3):1282-8. PubMed ID: 7932180 [TBL] [Abstract][Full Text] [Related]
19. Respirable powder formulation of a shortened vasoactive intestinal peptide analog for treatment of airway inflammatory diseases. Suzuki H; Mizumoto T; Seto Y; Sato H; Onoue S J Pept Sci; 2018 Mar; 24(3):. PubMed ID: 29441631 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacological properties of the N-terminal decapeptide of the vasoactive intestinal peptide (VIP). Bodanszky M; Henes JB; Yiotakis AE; Said SI J Med Chem; 1977 Nov; 20(11):1461-4. PubMed ID: 915906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]